Hijacking a chaperone: Manipulation of the MHC class II presentation pathway

Immunology Today

Volumn 21, Issue 11, 2000, Pages 546-550

  Koch, Norbert ^a   Van Driel, Ian R ^b   Gleeson, Paul A ^b  

^a UNIVERSITY OF BONN   (Germany)

^b MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; ENDOPLASMIC RETICULUM; ENDOSOME; GENETIC REGULATION; HUMAN; IMMUNE RESPONSE; MOLECULAR CLONING; PRIORITY JOURNAL; REVIEW; TECHNOLOGY;

EID: 0033667396     PISSN: 01675699     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5699(00)01717-5     Document Type: Note

References (36)

1. Accessory molecules for MHC class II peptide loading
2. Proteolysis in MHC class II antigen presentation: Who's in charge?
3. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages
4. Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO
5. Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing
6. The motif Tyr-X-X-hydrophobic residue mediates lysosomal membrane targeting of lysosome-associated membrane protein 1
7. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens
8. Presentation on class II MHC molecules of endogenous lysozyme targeted to the endocytic pathway
9. The MHC class II-associated invariant chain contains two endosomal targeting signals within its cytoplasmic tail
10. Surface expression of the invariant chain (CD74) is independent of concomitant expression of major histocompatibility complex class II antigens
11. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins
12. Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumour antigen
13. + T cells
14. Primary structure of the gene for the murine Ia antigen-associated invariant chains (Ii). An alternatively spliced exon encodes a cysteine-rich domain highly homologous to a repetitive sequence of thyroglobulin
15. Endosomal proteolysis and MHC class II function
16. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells
17. Positive selection of T cells induced by viral delivery of neopeptides to the thymus
18. C-terminal extension of the MHC class II-associated invariant chain by an antigenic sequence triggers activation of naive T cells
19. Identification of a sequence that mediates promiscuous binding of invariant chain to MHC class II allotypes
20. An altered invariant chain protein with an antigenic peptide in place of CLIP forms SDS-stable complexes with class II α β dimers and facilitates highly efficient peptide loading
21. Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP
22. Get into the groove! Targeting antigens to MHC class II
23. Requirement for diverse, low-abundance peptides in positive selection of T cells
24. Production of soluble MHC class II proteins with covalently bound single peptides
25. The repertoire of T cells shaped by a single MHC/peptide ligand
26. + T cells in the antitumour immune response
27. Therapeutic vaccination for cancer
28. Treatment of established tumours with a novel vaccine that enhances major histocompatibility class II presentation of tumour antigen
29. Antigen-specific immunotherapy for murine lung metastatic tumours expressing human papillomavirus type 16 E7 oncoprotein
30. + T lymphocytes
31. Discrete proteolytic intermediates in the MHC class I antigen processing pathway and MHC 1-dependent peptide trimming in the ER
32. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene
33. The evolution of self tolerance: A new cell is required to meet the challenge of self-reactivity
34. Targeting genes: Delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo
35. DNA vaccines: Immunology, application, and optimization
36. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation